Injectafer (ferric carboxymaltose; Vifor/Luitpold Pharmaceuticals/Zeria) is an iron maintenance treatment used to help elevate hemoglobin levels in patients with anemia in chronic kidney disease (CKD).
It is administered intravenously and is dissociated into iron and sucrose once in circulation. The iron is transported via transferrin to erythroid precursor cells. Erythroid precursor cells incorporate the iron into hemoglobin as the cell matures into a red blood cell. Iron maintenance therapies like Injectafer have achieved widespread use by improving both the safety and cost-efficiency associated with treating anemia in CKD, reducing the doses of erythropoiesis-stimulating agents required to correct and maintain hemoglobin levels.
Key Topics Covered:
List of Figures
Figure 1: Injectafer for anemia in chronic kidney disease - SWOT analysis
Figure 2: Drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 3: Drug assessment summary of Injectafer for anemia in chronic kidney disease
Figure 4: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country, 2015-24
List of Tables
Table 1: Injectafer drug profile
Table 2: Injectafer Phase III data in anemia in chronic kidney disease
Table 3: Injectafer sales for anemia in chronic kidney disease across the US and five major EU markets, by country ($m), 2015-24
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/w5n4j2/injectafer?w=4